Wire · operational-macro
FDA Approves Bepirovirsen Injection to Treat Chronic Hepatitis B
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 October 2026 · Fusion42 review
The FDA approved GSK's bepirovirsen injection for treating chronic hepatitis B in adults without cirrhosis, offering a finite treatment option combined with existing antivirals that can eliminate the need for ongoing medication. The approval includes a companion diagnostic and highlights pharmacists' expanding role in screening, patient counselling, and treatment management within communities.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 21 Oct 2026 and 22 Oct 2026.
◆ ◆ The Wire takeaway
You can now build hepatitis B treatments around a finite RNA-targeting drug, not lifelong antivirals. Pharmacists in community settings open new doors to test, educate, and manage patients.
◆ Coverage
3 sources · first reported 21 Oct 2026 · latest 22 Oct 2026
◆ Related on Wire
◆ Topics